Equity Profile

HALO

Halozyme Therapeutics, Inc.

Health CareBiotechnology$8.5B

May11Mon

Post-Earnings Recap

ReportedQ1-2026After Close4:01 PM EDT

Halozyme Therapeutics Beats on EPS, Stock Up 3.57%

Metric	Actual	Expected	Surprise
EPS	$1.60	$1.52	+9.74%
Revenue	—	$359M	—

management commentary, guidance changes, and full analysis available with Pro.

Halozyme Therapeutics Beats on EPS, Stock Up 3.57%

Key Numbers

Metric	Actual	Expected	Surprise
EPS	$1.60	$1.52	+9.74%
Revenue	—	$359M	—

Management Commentary

Tone: Unknown

No transcript is on record for this earnings call, and the analysis is based solely on numerical results.

What It Means

Halozyme Therapeutics reported a strong earnings per share, exceeding expectations by nearly 10%. However, revenue figures were not disclosed, leaving some uncertainty. The stock reacted positively, increasing by 3.57%, likely driven by the better-than-expected EPS performance.

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$1.52

Revenue

Revenue figures will provide insights into the company's sales performance and market demand for its products.

$359M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases. Operating in the health care sector, Halozyme is known for its proprietary enzyme technology that enhances the delivery of biologic drugs, which is increasingly important as the demand for effective treatments grows.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q4-2025, Halozyme reported an EPS of -$0.24, significantly missing analyst expectations of $2.06. This disappointing performance led to a modest stock increase of 1.31% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts are cautiously optimistic about Halozyme's upcoming earnings, expecting an EPS of $1.52 and revenue of $359 million. The company has a strong track record of beating EPS estimates, which could lead to positive market reactions.

Bull Case

If Halozyme meets or exceeds EPS expectations, it could signal strong operational performance and boost investor confidence, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company misses earnings expectations again, it may raise concerns about its financial health and management effectiveness, leading to a negative reaction in the stock price.

Key Metrics to Watch

EPS

$1.52

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$359M

Revenue figures will provide insights into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Halozyme achieve an EPS of at least $1.52?

This figure is critical as it reflects the company's ability to generate profit and meet market expectations, which could significantly influence stock performance.

What are the revenue figures compared to the expected $359 million?

Revenue performance will indicate market demand for Halozyme's products and its overall financial health, impacting investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Halozyme to exceed its EPS expectations due to its strong history of beating estimates, despite recent setbacks.

Supporting Evidence

Halozyme has an 88% EPS beat rate in recent quarters, indicating a strong likelihood of positive surprises.

The stock has shown resilience with modest increases following earnings misses, suggesting underlying strength.

Options are pricing a 5.2% move, which is higher than the historical average, indicating that the market may be overly cautious.

Key Risk

If Halozyme's revenue exceeds $378 million, it could significantly alter the market's perception of its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these earnings figures as they will determine the company's financial trajectory and investor sentiment.

Bull Confirmed If

Achieving an EPS of $1.52 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.42 would raise serious concerns about the company's profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±5.2%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a potential move of about 5.2% in either direction following the earnings report, indicating heightened uncertainty among investors.

Options are pricing ±5.6% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

27.8%

Calls (35K)P/C Ratio: 0.16Puts (12K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 6 of 12 (50%)

This setup has occurred 30 times across Health Care in the last 2 years. 6 of 12 faded and 6 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 4.5%, with a raw directional average of -0.4% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests the stock could rise by around 0.10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further commentary from management.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around 1.31% on the first day, raising concerns about its financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships that could drive revenue.
2Management's commentary on market demand for Halozyme's therapies.
3Insights into cost management and operational efficiency improvements.
4Details on any ongoing clinical trials and their expected outcomes.
5Guidance on future revenue projections and market strategies.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May8

HEReported

Hawaiian Electric Industries, Inc.

RecapView

May8

JHGReported

Company Snapshot

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies for patients with serious diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

$1.52

Revenue

Revenue figures will provide insights into the company's sales performance and market demand for its products.

$359M

Wall Street expectations, options signals, track record, and call prep available with Pro.

Original Pre-Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+5.95%

Avg Stock Reaction

+0.59%

Last Quarter Recap

In Q4-2025, Halozyme reported an EPS of -$0.24, significantly missing analyst expectations of $2.06. This disappointing performance led to a modest stock increase of 1.31% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Halozyme meets or exceeds EPS expectations, it could signal strong operational performance and boost investor confidence, potentially leading to a significant stock price increase.

Bear Case

Conversely, if the company misses earnings expectations again, it may raise concerns about its financial health and management effectiveness, leading to a negative reaction in the stock price.

Key Metrics to Watch

EPS

$1.52

Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and revenues.

Revenue

$359M

Revenue figures will provide insights into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Halozyme achieve an EPS of at least $1.52?

This figure is critical as it reflects the company's ability to generate profit and meet market expectations, which could significantly influence stock performance.

What are the revenue figures compared to the expected $359 million?

Revenue performance will indicate market demand for Halozyme's products and its overall financial health, impacting investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Halozyme to exceed its EPS expectations due to its strong history of beating estimates, despite recent setbacks.

Supporting Evidence

Halozyme has an 88% EPS beat rate in recent quarters, indicating a strong likelihood of positive surprises.

The stock has shown resilience with modest increases following earnings misses, suggesting underlying strength.

Options are pricing a 5.2% move, which is higher than the historical average, indicating that the market may be overly cautious.

Key Risk

If Halozyme's revenue exceeds $378 million, it could significantly alter the market's perception of its growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching these earnings figures as they will determine the company's financial trajectory and investor sentiment.

Bull Confirmed If

Achieving an EPS of $1.52 or higher would confirm strong operational performance and investor confidence.

Bear Confirmed If

An EPS below $1.42 would raise serious concerns about the company's profitability and growth prospects.

Pre-Earnings Positioning

Options Market

Implied Move

±5.2%

Historical Avg

±1.4%

Pricing rich

The options market is pricing in a potential move of about 5.2% in either direction following the earnings report, indicating heightened uncertainty among investors.

Options are pricing ±5.6% while HALO has averaged ±1.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

27.8%

Calls (35K)P/C Ratio: 0.16Puts (12K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 6 of 12 (50%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Halozyme beats expectations, history suggests the stock could rise by around 0.10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further commentary from management.

Miss

Should the company miss earnings expectations, history suggests a potential decline of around 1.31% on the first day, raising concerns about its financial health.

Preparation

Congressional Activity

House & Senate STOCK Act disclosures over the trailing 6 months.

Trades

1 buy·0 sells

Members

House only

Est. Notional

$1,001.00–$15,000.00

disclosed dollar ranges

Most Active Members

D-CAGilbert CisnerosRep.
1

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches or partnerships that could drive revenue.
2Management's commentary on market demand for Halozyme's therapies.
3Insights into cost management and operational efficiency improvements.
4Details on any ongoing clinical trials and their expected outcomes.
5Guidance on future revenue projections and market strategies.